Search over 3,000 reports

    Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025

    Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025
    Date: Jul, 2017
    Type: Pharmaceutical Industry Report
    Pages: 221
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DISR0009
    DelveInsight's "Cutaneous T-Cell Lymphoma - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2025"report provides an overview of the disease, the comprehensive insights on the competitive landscape and market of Cutaneous T-Cell Lymphoma.

    The Report covers detailed historical and forecasted epidemiology of Cutaneous T-Cell Lymphoma(CTCL) in the 7MM (till 2025), segmented on the basis of sub-types (Mycosis fungoides, Sezary syndrome and others i.e., Primary cutaneous peripheral T-cell lymphoma, ATLL, primary cutaneous CD30+ T-cell lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and unspecified), gender (predominant in males) as well as stages of the disease (Early Stage and Late Stage).
    The Report also includes market trends of the Cutaneous T-Cell Lymphoma for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, and UK) and Japan. The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Cutaneous T-Cell Lymphoma from 2017 to 2025 segmented by seven major markets. In addition, the report also covers market drivers, market barriers and unmet medical need.

    The competitive landscape of the report covers both pipeline and marketed portfolio of the indication. Cutaneous T-Cell Lymphoma pipeline provides information on the therapeutic drugs in development and comparative analysis at various stages covering clinical and pre-clinical & discovery stages, therapeutics assessment by Monotherapy/Combination products and Molecule Type drug analysis. It also provides in-depth analysis on the Phase III profile covering clinical trial studies, recent developments and SWOT Analysis.

    The United States accounts for the highest incident population of CTCL in comparison to EU5 countries and Japan. According to DelveInsight, it is estimated that the incident cases of CTCL in the United States shall increase at a CAGR of 0.35% from 2013 to 2025.
    The treatment of CTCL depends on the disease stage. Early stage therapies are topical, including corticosteroids, retinoids, imiquimod (Aldara), ultraviolet A irradiation (PUVA), and total skin electron beam therapy. Systemic therapies are introduced in the advanced stages where the disease is widespread and/or resistant to topical treatment. These include interferon alpha injections, stem cell transplant, alemtuzumab (MabCampath) and other chemotherapy regimens. The FDA approved drugs are Istodax (romidepsin), Valchlor (mechlorethamine), Uvadex (methoxsalen), Targretin (bexarotene) and Zolinza (vorinostat). The drugs have been considered in our report as per NCCN (United States) guidelines.

    Amongst all the 7MM, United States accounts for highest market share for CTCL due to high incidence as well as due to high annual cost of therapy. According to DelveInsight, the Cutaneous T-Cell Lymphoma market size in 7MM is estimated to increase at a compound annual growth rate (CAGR) of 1.6% for the forecasted period i.e., 2013-2025.

    Scope of the report

    • Overview of the Global pipeline scenario for Cutaneous T-Cell Lymphoma , products and associated companies information
    • Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities.
    • The Report provides detailed historical and forecasted epidemiological data of Cutaneous T-Cell Lymphoma in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
    • Organize sales and marketing efforts by identifying the best opportunities for Cutaneous T-Cell Lymphoma in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan.
    • To understand the future market competition in the global Cutaneous T-Cell Lymphoma market and Insightful review of the key market drivers and barriers.
    • The report will help in developing business strategies by understanding the trends shaping and driving the global Cutaneous T-Cell Lymphoma market.
    • Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis
    • The Report also covers the detailed historical and forecasted Cutaneous T-Cell Lymphoma market covering United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2013-2025.
    Report Introduction
    Cutaneous T- Cell Lymphoma Market Overview at a Glance
    Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2016
    Total Market Share Distribution of Cutaneous T- Cell Lymphoma for 7 MM in 2025
    Cutaneous T- Cell Lymphoma
    o Introduction
    o Types
    o Causes
    o Pathophysiology
    o Symptoms
    o Diagnosis
    Epidemiology of Cutaneous T-Cell Lymphoma
    United States
    o Assumptions and Rationale
    o Incident Population of Cutaneous T-Cell Lymphoma
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United States
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United States
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States
    Europe
    o Assumptions and Rationale
    Germany
    o Incident Population of Cutaneous T-Cell Lymphoma in Germany
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany
    France
    o Incident Population of Cutaneous T-Cell Lymphoma in France
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France
    Italy
    o Incident Population of Cutaneous T-Cell Lymphoma in Italy
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy
    Spain
    o Incident Population of Cutaneous T-Cell Lymphoma in Spain
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain
    United Kingdom
    o Incident Population of Cutaneous T-Cell Lymphoma in UK
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in United Kingdom
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK
    Japan
    o Incident Population of Cutaneous T-Cell Lymphoma in Japan
    o Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
    o Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
    o Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan
    Treatment Algorithm
    o International Lymphoma Radiation Oncology Group Guidelines for Modern Radiation Therapy for Primary Cutaneous Lymphomas
    o United States
    ? NCCN Guidelines
    o Europe
    ? ESMO Guidelines
    ? Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group Guidelines
    ? EORTC recommendations for the treatment of mycosis fungoides/Se´zary syndrome
    Unmet Needs
    Competitive Marketed Drug Landscape
    o Istodax (Romidepsin): Celgene Corporation
    ? Drug Description
    ? Mechanism of Action
    ? Advantages & Disadvantages
    ? Safety and Efficacy
    ? Product Profile
    Marketed Drug List Continued…
    Competitive Pipeline Landscape
    o Emerging Therapies
    ? Brentuximab Vedotin: Seattle Genetics
    ? Product Description
    ? Research and Development
    ? Product Development Activities
    ? Product Profile
    Emerging Drug List Continued…
    o Comparative Analysis
    ? Clinical Stage Products
    ? Pre-Clinical Stage Products
    o Therapeutic Assessment
    ? Assessment by Monotherapy Products
    ? Assessment by Combination Products
    ? Assessment by Route of Administration
    ? Assessment by Stage and Route of Administration
    ? Assessment by Molecule Type
    ? Assessment by Stage and Molecule Type
    ? Assessment by Domain
    ? Assessment by Stage and Domain
    Cutaneous T- Cell Lymphoma: Country-Wise Market Analysis
    Total Market Size of Cutaneous T- Cell Lymphoma for 7 MM in 2013-2025
    United States
    o Market Size of CTCL in United States
    o Stage-Specific Market Size(Early&Late) of CTCL in United States
    Europe
    Germany
    o Market Size of CTCL in Germany
    o Stage-Specific Market Size(Early&Late) of CTCL in Germany
    France
    o Market Size of CTCL in France
    o Stage-Specific Market Size(Early&Late) of CTCL in France
    Italy
    o Market Size of CTCL in Italy
    o Stage-Specific Market Size(Early&Late) of CTCL in Italy
    Spain
    o Market Size of CTCL in Spain
    o Stage-Specific Market Size(Early&Late) of CTCL in Spain
    United Kingdom
    o Market Size of CTCL in United Kingdom
    o Stage-Specific Market Size(Early&Late) of CTCL in United Kingdom
    Japan
    o Market Size of CTCL in Japan
    o Stage-Specific Market Size(Early&Late) of CTCL in Japan
    Market Drivers
    Market Restraints
    Appendix
    Report Methodology
    Consulting Services
    Disclaimer
    About DelveInsight
    Table 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
    Table 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
    Table 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
    Table 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
    Table 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Table 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Table 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Table 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Table 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Table 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Table 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Table 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Table 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
    Table 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Table 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Table 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Table 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Table 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Table 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Table 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Table 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
    Table 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Table 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Table 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Table 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
    Table 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Table 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Table 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Table 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
    Table 30:Clinical Trials by Recruitment status, 2017
    Table 31: Number of Products under development by Companies, 2017
    Table 32: Clinical Stage Products, 2017
    Table 33: Pre-Clinical Stage Products, 2017
    Table 34: Assessment by Monotherapy Products, 2017
    Table 35: Assessment by Combination Products, 2017
    Table 36: Assessment by Route Of Administration, 2017
    Table 37: Assessment by Stage and Route Of Administration, 2017
    Table 38: Assessment by Molecule Type, 2017
    Table 39: Assessment by Stage and Molecule Type, 2017
    Table 40: Assessment by Stage of development and Domain, 2017
    Table 41: Recommendations for treatment of CTCL by Radiation Therapy
    Table 42: Recommendations for treatment of MF stages IA, IB, and IIA
    Table 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
    Table 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
    Table 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
    Table 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
    Table 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
    Table 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
    Table 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
    Table 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
    Table 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Table 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
    Figure 1: Incident Population of Cutaneous T-Cell Lymphoma in United States (2013-2025)
    Figure 2: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
    Figure 3: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in US (2013-2025)
    Figure 4: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in United States (2013-2025)
    Figure 5: Incident Population of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Figure 6: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Figure 7: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Figure 8: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Germany (2013-2025)
    Figure 9: Incident Population of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Figure 10: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Figure 11: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Figure 12: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in France (2013-2025)
    Figure 13: Incident Population of Cutaneous T-Cell Lymphoma Italy (2013-2025)
    Figure 14: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Figure 15: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Figure 16: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Italy (2013-2025)
    Figure 17: Incident Population of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Figure 18: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Figure 19: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Figure 20: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Spain (2013-2025)
    Figure 21: Incident Population of Cutaneous T-Cell United Kingdom (2013-2025)
    Figure 22: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Figure 23: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Figure 24: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in UK (2013-2025)
    Figure 25: Incident Population of Cutaneous T-Cell Japan (2013-2025)
    Figure 26: Sub-type Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Figure 27: Gender Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Figure 28: Stage-Specific Incidence of Cutaneous T-Cell Lymphoma in Japan (2013-2025)
    Figure 29: Brentuximab Vedotin, Clinical Trials by Zone, 2017
    Figure 30:Clinical Trials by Recruitment status, 2017
    Figure 31: Number of Products under development by Companies, 2017
    Figure 32: Clinical Stage Products, 2017
    Figure 33: Pre-Clinical Stage Products, 2017
    Figure 34: Assessment by Monotherapy Products, 2017
    Figure 35: Assessment by Combination Products, 2017
    Figure 36: Assessment by Route Of Administration, 2017
    Figure 37: Assessment by Stage and Route Of Administration, 2017
    Figure 38: Assessment by Molecule Type, 2017
    Figure 39: Assessment by Stage and Molecule Type, 2017
    Figure 40: Assessment by Stage of development and Domain, 2017
    Figure 41: Recommendations for treatment of CTCL by Radiation Therapy
    Figure 42: Recommendations for treatment of MF stages IA, IB, and IIA
    Figure 43: List of Marketed Drugs for Cutaneous T Cell Lymphoma
    Figure 44: Market Size of Cutaneous T-cell Lymphoma in 7MM (USD Million) (2013-2025)
    Figure 45: United States Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 46: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United States in USD, Million (2013-2025)
    Figure 47: Germany Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 48: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma inGermany in USD, Million (2013-2025)
    Figure 49: France Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 50: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in France in USD, Million (2013-2025)
    Figure 51: Italy Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 52: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Italy in USD, Million (2013-2025)
    Figure 53: Spain Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 54: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Spain in USD, Million (2013-2025)
    Figure 55: United Kingdom Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 56: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in United Kingdom in USD, Million (2013-2025)
    Figure 57: Japan Market Size of Cutaneous T-Cell Lymphoma in USD, Million (2013-2025)
    Figure 58: Stage-Specific (Early&Late) Market Size of Cutaneous T-Cell Lymphoma in Japan in USD, Million (2013-2025)
    • Celgene Corporation

    • Kyowa Hakko Kirin Co, Ltd.

    • Actelion Pharmaceuticals

    • Mallinckrodt Pharmaceuticals

    • Eisai Co., Ltd.

    • Merck Sharp & Dohme Corp.

    • Seattle Genetics

    • Soligenix

    • Janssen

    • 4SC AG

    • Medivir AB

    • Single User License
      $6,950.00
    • Site License
      $13,900.00
    • Global License
      $20,850.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap